Vitamin D and vitamin B12 deficiencies are common in patients with midgut carcinoid (SI-NET)

Lind, Anna-Karin; Wängberg, Bo; Ellegård, Lars

doi:10.1038/ejcn.2016.40

Cited by 25 publications

(32 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…GEP-NET patients seem susceptible to developing osteopenia and osteoporosis. As mentioned above, only one study demonstrated low bone density in NET patients [18], while several studies described a considerable percentage of vitamin D deficiency and insufficiency [21,22,29,30] in this category of patients.…”

Section: Clinical Management Of Bone Health and Vitamin D Supplementamentioning

confidence: 95%

“…As mentioned above, GEP-NET patients have an increased risk of malnutrition due to tumor hormonal secretion and treatments, which affect the absorption of nutrients, including vitamin D [19]. Vitamin D deficiency, defined as 25(OH)D levels ≤20 ng/mL (≤50 nmol/L) and insufficiency, defined as 25(OH)D levels ranging from 20 to 29.9 ng/mL (52-72 nmol/L) [105], is described in between 46% and 81% of patients with NET (Table 1) [21,22,29,30]. This large range observed in the prevalence of vitamin D deficiency or insufficiency could be due to several factors, including latitude of the country, seasons and different assays used for the measurements of vitamin D levels [106,107].…”

Section: Vitamin D In Gep-netmentioning

confidence: 99%

“…This large range observed in the prevalence of vitamin D deficiency or insufficiency could be due to several factors, including latitude of the country, seasons and different assays used for the measurements of vitamin D levels [106,107]. Lind et al found a high prevalence of low BMD (82% of cases) and of vitamin D and B12 deficiency (74% and 32% of cases, respectively) in a cohort of 50 patients with small intestinal NET [21]. In a recent study, Massironi et al found vitamin D deficiency in 33% and insufficiency in 68% of cases in an Italian population of 138 GEP-NET patients [22].…”

Section: Vitamin D In Gep-netmentioning

confidence: 99%

“…In conclusion, few studies have evaluated vitamin D status in GEP-NET patients and they have focused on the differences in clinical outcomes between patients with insufficient/deficient levels of vitamin D vs. patients with sufficient vitamin D levels (Table 1). Only one study also reported the incidence of low BMD; however, without correlating BMD value with vitamin D levels [21]. Further studies are needed to better elucidate the role of vitamin D in GEP-NET and to investigate a relationship between vitamin D, BMD, and osteoporosis in GEP-NET patients.…”

Section: Vitamin D In Gep-netmentioning

confidence: 99%

“…It has been demonstrated that NET patients have a greater clinical burden of disease than matched control subjects, with increased risk of cardiovascular, hepatic, and gastrointestinal diseases, as well as osteopenia and osteoporosis [18]. Moreover, the tumor itself and the systemic therapy may have an impact on patients' nutritional status [19,20], leading to a deficiency of different vitamins, including vitamin D [21,22]. It is well demonstrated that vitamin D plays a key role in the process of bone formation [23].…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Bone Metabolism and Vitamin D Implication in Gastroenteropancreatic Neuroendocrine Tumors

Altieri¹,

Dato

Modica

et al. 2020

Nutrients

View full text Add to dashboard Cite

Patients affected by gastroenteropancreatic–neuroendocrine tumors (GEP–NETs) have an increased risk of developing osteopenia and osteoporosis, as several factors impact on bone metabolism in these patients. In fact, besides the direct effect of bone metastasis, bone health can be affected by hormone hypersecretion (including serotonin, cortisol, and parathyroid hormone-related protein), specific microRNAs, nutritional status (which in turn could be affected by medical and surgical treatments), and vitamin D deficiency. In patients with multiple endocrine neoplasia type 1 (MEN1), a hereditary syndrome associated with NET occurrence, bone damage may carry other consequences. Osteoporosis may negatively impact on the quality of life of these patients and can increment the cost of medical care since these patients usually live with their disease for a long time. However, recommendations suggesting screening to assess bone health in GEP–NET patients are missing. The aim of this review is to critically analyze evidence on the mechanisms that could have a potential impact on bone health in patients affected by GEP–NET, focusing on vitamin D and its role in GEP–NET, as well as on factors associated with MEN1 that could have an impact on bone homeostasis.

show abstract

Section: Clinical Management Of Bone Health and Vitamin D Supplementamentioning

confidence: 95%

Section: Vitamin D In Gep-netmentioning

confidence: 99%

Section: Vitamin D In Gep-netmentioning

confidence: 99%

Section: Vitamin D In Gep-netmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Bone Metabolism and Vitamin D Implication in Gastroenteropancreatic Neuroendocrine Tumors

Altieri¹,

Dato

Modica

et al. 2020

Nutrients

View full text Add to dashboard Cite

show abstract

Supportive therapy in gastroenteropancreatic neuroendocrine tumors: Often forgotten but important

Jin

Spampatti

Spitzweg

et al. 2018

Rev Endocr Metab Disord

View full text Add to dashboard Cite

Neuroendocrine tumors (NETs) are a group of rare and heterogeneous malignancies that can develop in various organs. A significant number of gastroenteropancreatic neuroendocrine tumours (GEP-NETs) is functionally active and presents with symptoms related to the secretion of biologically active substances, leading to the development of distinct clinical syndromes. There are various therapeutic approaches for GEP-NETs, including curative surgery, palliative surgery, local-ablative and loco-regional therapies as well as systemic therapeutic options including peptide receptor radionuclide therapy, cytotoxic therapy, and molecularly targeted therapies. Specific supportive therapy of patients with NETs includes management or prevention of hormone-related clinical syndromes and paraneoplastic states. Supportive therapy plays a key role in NET treatment. Supportive therapy includes debulking surgery and interventional radiologic techniques to reduce tumour bulk or load, as well as systemic medical treatment options to manage or prevent hypersecretion syndromes and treatment-related side effects. Supportive therapies are a type of of comprehensive treatment addressing the patient as a whole person throughout the process of NET treatment. Therefore, supportive therapy also encompasses psychosocial support, expert nursing, nutritional support and management of cancer related pain.

show abstract

Sarcopenia and Neuroendocrine Neoplasms

Clement,

Brown,

Leerdam

et al. 2024

Curr Oncol Rep

View full text Add to dashboard Cite

Vitamin D and vitamin B12 deficiencies are common in patients with midgut carcinoid (SI-NET)

Cited by 25 publications

References 13 publications

Bone Metabolism and Vitamin D Implication in Gastroenteropancreatic Neuroendocrine Tumors

Bone Metabolism and Vitamin D Implication in Gastroenteropancreatic Neuroendocrine Tumors

Supportive therapy in gastroenteropancreatic neuroendocrine tumors: Often forgotten but important

Sarcopenia and Neuroendocrine Neoplasms

Contact Info

Product

Resources

About